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Acquiring evidence for precision prostate
cancer care
In the current issue of Annals of Oncology, Romero-Laorden et al.
[1] report the case of a patient with metastatic castration-resistant
prostate cancer (mCRPC) who achieved a significant tumour re-
sponse to the PARP inhibitor veliparib administered as a single
agent. Molecular studies on this patient’s primary and metastatic
tumour tissue samples revealed a homozygous deletion of BRCA2
as the putative mechanism determining PARP inhibitor sensitivity,
although the authors describe genomic heterogeneity for this event
within the primary tumour.
The use of PARP inhibitors against BRCA1/BRCA2 defective
tumours, based on applying the biological concept of synthetic
lethality to cancer treatment, has been a clinically important ad-
vance in precision cancer medicine [2–4]. Defects in DNA repair
genes, particularly in those involved in double-strand error-free
homologous recombination (HR) mediated repair (i.e. BRCA1,
BRCA2, ATM, PALB2, CDK12, FANCA and others), have been
identified in a proportion of advanced prostate cancers [5, 6].
While this disease is primarily driven by androgen-signalling,
emerging data over the last few years indicate that BRCA1/2-
defective metastatic prostate cancers, representing 10–14% of
the overall mCRPC population, could respond to alternative
approaches such as PARP inhibitors or platinum chemotherapy
[7, 8]. Tumour responses in cases harbouring other HR gene aber-
rations have also been described. Some of these mutations have
been also reported to confer worse prognosis from prostate cancer
[9, 10]. These data are currently being explored in several clinical
trials with four different compounds, and the PARP inhibitor ola-
parib has been given Breakthrough Designation by the FDA based
on data in this disease.
Despite multiple recent advances in prostate cancer care, with
several new therapies approved for advanced disease based on sur-
vival benefit in randomized trials, molecular stratification strat-
egies have not been incorporated into prostate cancer patient care
so far. Presently, stratification of patients for Androgen Receptor
(AR)-targeting agents based on AR aberrations [11–14] and treat-
ment with DNA repair targeting agents for patients harbouring
DNA repair defects constitute two promising opportunities for
more precise care of advanced prostate cancer. Randomized trials
need now to prove the benefit of such approaches to transfer these
into clinical practice. Implementation of such multiplexed mo-
lecular testing to patient care does however present challenges that
will have to be addressed towards guaranteeing clinical qualifica-
tion of these biomarkers.
The first challenge arises from the need for rigorous validation
of assays used at each centre and homogenization of biomarker
assays across centres. Panel or more comprehensive whole exome
sequencing requires laborious bioinformatic analyses, which are
not yet standardized. Collaboration between regulatory agencies,
academics and industry is critical for success, and all parts need
to be involved in the design of clinical trials focused on testing
precision medicine approaches. In the particular case of DNA re-
pair defects and prostate cancer, we envision a multiplexed bio-
marker assay may be necessary, as different genes have been
shown to associate with sensitivity to PARP inhibition. The FDA
has already started considering how to adapt the regulatory
framework to this new scenario and how to efficiently integrate
post-marketing data review [15].
Intra-patient genomic heterogeneity represents a second major
challenge for precision medicine [16]. Molecular studies to date
predominantly using single site tissue biopsies, either from the
primary tumour or metastases, are insufficient to comprehen-
sively integrate temporal or spatial tumour evolution data. In the
case reported here, the authors identified a somatic BRCA2
homozygous deletion in bone metastatic tissue sample by tar-
geted next-generation sequencing. They then studied the prosta-
tectomy specimen collected 2.5 years before and identified areas
of homozygous and heterozygous loss of the BRCA2 gene region
by FISH. The questions arising then are: would the BRCA2 loss
have been missed if this patient had been assessed based on stand-
ard random biopsies of the original prostate tumour? Moving
forward, can we rely on archival prostate tumour samples, nor-
mally small blocks that have been in paraffin for years, to stratify
mCRPC patients for somatic DNA repair defects?
Primary prostate cancers are essentially multifocal tumours, so
spatial genomic heterogeneity in primary tumours is inherent
[17] Treatment-mediated selective pressure before, or during, the
development of metastatic disease facilitates the selection of the
resistant clone or clones [18]. Also, polyclonal seeding and seed-
ing between metastases has been described and may contribute to
this selection process [19]. All these elements may confer a lower
degree of heterogeneity for advanced disease, but this would still
be a relevant feature to consider when stratifying patients.
Circulating biomarkers such as circulating-free DNA (cfDNA)
and circulating tumour cells (CTC) are promising sources for ob-
taining tumour genomic material through a minimally invasive
form of a liquid biopsy that can be repeated over time to account
for tumour evolution. Sequencing of cfDNA can provide muta-
tional data from different metastases represented in cfDNA and
can be used to monitor evolution in response and resistance to
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treatment [11, 20]. However, only a fraction of cfDNA comes
from tumour cells, and therefore in cases with low tumour con-
tent, particularly in earlier stages of the disease, assessment can be
challenging, particularly for copy number alterations. Assay de-
velopment should permit, within a few years, the addressing of
these issues. Circulating tumour cell analyses also permits single-
cell molecular characterization and therefore represent another
possible biomarker for spatial heterogeneity assessment; how-
ever, the costs and complexity of these assays still prevent
population-wide testing outside academic institutions.
Moreover, not all clones or metastases may be contributing
equally to circulating tumour genomic material. The key ques-
tion then is: how much of this heterogeneity is clinically relevant
in defining sensitivity to a certain treatment?
In conclusion, this case reported by Romero-Laorden et al. is
in line with previously published data, supporting evidence that a
molecularly defined subset of prostate cancer patients could
benefit from PARP inhibitors. Large clinical trials are ongoing to
validate these promising data. This case also highlights some of
the challenges that need to be addressed to successfully advance
the more precise care of mCRPC patients. We envision sequenc-
ing circulating tumour genomic material, in the forms of cfDNA
and CTC, to circumvent the limitations of single site biopsies.
J. Mateo, S. Carreira & J. S. de Bono*
Prostate Cancer Targeted Therapy Group, The Institute of Cancer
Research and The Royal Marsden NHS Foundation Trust, London, UK
(*E-mail: johann.debono@icr.ac.uk)
Funding
The authors acknowledge funding from Prostate Cancer UK,
Prostate Cancer Foundation, Movember, Stand Up To Cancer,
US Department of Defense, Cancer Research UK, UK
Department of Health, Academy of Medical Sciences and NHS
funding to the NIHR Biomedical Research Centre at the Royal
Marsden and The Institute of Cancer Research (no grant num-
bers apply). JM is supported by a Prostate Cancer Foundation
Young Investigator Award (PCF-16-YOUN11) and a Prostate
Cancer UK—Medical Research Council Fellowship (MR/
M003272/1).
Disclosure
All authors are employees of the Institute of Cancer Research
(London, UK), which is a joint applicant for the patent entitled
‘DNA damage repair inhibitors for treatment of cancer’ which in-
cludes the granted application US8143241. JSB has served as an
advisor for AstraZeneca, Medivation, Pfizer, Merck, Tesaro and
Biomarin.
References
1. Romero-Laorden N, Pi~neiro-Ya~nez E, Gutierrez-Pecharroman A et al.
Somatic BRCA2 bi-allelic loss in the primary prostate cancer was
associated to objective response to PARPi in a sporadic CRPC patient.
Ann Oncol 2017; 28(5): 1158–1159.
2. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in
BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035):
917–921.
3. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-
deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Nature 2005; 434(7035): 913–917.
4. Fong PCP, Boss DDS, Yap TA et al. Inhibition of poly (ADP-ribose)
polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;
361(2): 123–134.
5. Robinson D, Van Allen EM, Wu Y-M et al. Integrative clinical genomics
of advanced prostate cancer. Cell 2015; 161(5): 1215–1228.
6. Pritchard CC, Mateo J, Walsh MF et al. Inherited DNA-repair gene mu-
tations in men with metastatic prostate cancer. N Engl J Med 2016;
375(5): 443–453.
7. Mateo J, Carreira S, Sandhu S et al. DNA-repair defects and olaparib in
metastatic prostate cancer. N Engl J Med 2015; 373(18): 1697–1708.
8. Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic
inactivation of BRCA2 in platinum-sensitive metastatic castration-
resistant prostate cancer. Eur Urol 2016; 69(6): 992–995.
9. Castro E, Goh C, Olmos D et al. Germline BRCA mutations are associ-
ated with higher risk of nodal involvement, distant metastasis, and poor
survival outcomes in prostate cancer. J Clin Oncol 2013; 31(14):
1748–1757.
10. Castro E, Goh C, Leongamornlert D et al. Effect of BRCA mutations on
metastatic relapse and cause-specific survival after radical treatment for
localised prostate cancer. Eur Urol 2015; 68(2): 186–193.
11. Romanel A, Tandefelt DG, Conteduca V et al. Plasma AR and
abiraterone-resistant prostate cancer. Sci Transl Med 2015; 7(312):
312re10–312re10.
12. Henzler C, Li Y, Yang R et al. Truncation and constitutive activation of
the androgen receptor by diverse genomic rearrangements in prostate
cancer. Nat Commun 2016; 7: 13668.
13. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzaluta-
mide and abiraterone in prostate cancer. N Engl J Med 2014; 371(11):
1028–1038.
14. De Laere B, van Dam P-J, Whitington T et al. Comprehensive profiling
of the androgen receptor in liquid biopsies from castration-resistant
prostate cancer reveals novel intra-AR structural variation and splice
variant expression patterns. Eur Urol 2017 [Epub ahead of print], doi:
10.1016/j.eururo.2017.01.011; pii: S0302-2838(17)30018-0.
15. Evans BJ, Burke W, Jarvik GP. Special Report: The FDA and Genomic
Tests—Getting Regulation Right 2015; 372: 2258–2264.
16. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and
branched evolution revealed by multiregion sequencing. N Engl J Med
2012; 366(10): 883–892.
17. Boutros PC, Fraser M, Harding NJ et al. Spatial genomic heterogeneity
within localized, multifocal prostate cancer. Nat Genet 2015; 47(7):
736–745.
18. Kumar A, Coleman I, Morrissey C et al. Substantial interindividual and
limited intraindividual genomic diversity among tumors from men with
metastatic prostate cancer. Nat Med 2016; 22(4): 369–378.
19. Gundem G, Van Loo P, Kremeyer B et al. The evolutionary history of le-
thal metastatic prostate cancer. Nature 2015; 520(7547): 353–357.
20. Carreira S, Romanel A, Goodall J et al. Tumor clone dynamics in lethal
prostate cancer. Sci Transl Med 2014; 6(254): 254ra125.
doi:10.1093/annonc/mdx105
Published online 13 April 2017
Annals of Oncology Editorials
Volume 28 | Issue 5 | 2017 doi:10.1093/annonc/mdx105 | 917
